Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus

Diabetes Therapy

Volumn 4, Issue 2, 2013, Pages 331-345

  Heise, Tim ^a   Seman, Leo ^b   Macha, Sreeraj ^b   Jones, Peter ^c   Marquart, Alexandra ^d   Pinnetti, Sabine ^d   Woerle, Hans J ^d   Dugi, Klaus ^d  

^a Profil Institut fur Stoffwechselforschung GmbH   (Germany)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^c With Confidence Ltd   (United Kingdom)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Bi 10773; Diabetes; Empagliflozin; Pharmacodynamics; Pharmacokinetics; Safety; Tolerability

Indexed keywords

ALANINE AMINOTRANSFERASE; CALCIUM; CREATININE; EMPAGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; POTASSIUM; SODIUM; TRIACYLGLYCEROL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSURIA; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPOGLYCEMIA; KIDNEY TUBULE ABSORPTION; MALE; MAXIMUM PLASMA CONCENTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84887072459     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-013-0030-2     Document Type: Article

References (27)

1. Cefalu WT, Richards RJ, Melendez-Ramirez LY. Redefining treatment success in type 2 diabetes mellitus: comprehensive targeting of core defects. Cleve Clin J Med. 2009;76:S39-47.
2. Inzucchi SE, Bergenstal RM, Buse JB, et al. American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364-79.
3. Cheung BM, Ong KL, Cherny SS, Sham PC, Tso AW, Lam KS. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med. 2009;122:443-53.
4. Gerstein HC, Swedberg K, Carlsson J, CHARM Program Investigators, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-59.
5. Duckworth W, Abraira C, Moritz T, VADT Investigators, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129-39.
6. Patel A, MacMahon S, Chalmers J, ADVANCE Collaborative Group, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-72.
7. DeSouza C, Fonseca V. Therapeutic targets to reduce cardiovascular disease in type 2 diabetes. Nat Rev Drug Discov. 2009;8:361-7.
8. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ. 2001;343:d4169.
9. Schernthaner G, Barnett AH, Betteridge DJ, et al. Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia. 2010;53:1258-69.
10. Preiss D, Ray KK. Intensive glucose lowering treatment in type 2 diabetes. BMJ. 2011;343:d4243.
11. Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med. 2010;27:136-42.
12. Ferrannini E. Learning from glycosuria. Diabetes. 2011;60:695-6.
13. Mather A, Pollock C. Renal glucose transporters: novel targets for hyperglycemia management. Nat Rev Nephrol. 2011;6:307-11.
14. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:2223-33.
15. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010;33:2217-24.
16. Zhang L, Feng Y, List J, Kasichayanula S, Pfister M. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes Obes Metab. 2010;12:510-6.
17. Wilding JP, Norwood P, T'joen C, Bastien A, List JF, Fiedorek FT. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care. 2009;32:1656-62.
18. Rosenstock J, Arbit D, Usiskin K, Capuano G, Canovatchel W. Canagliflozin, an inhibitor of sodium glucose co-transporter 2 (SGLT2), improves glycemic control and lowers body weight in subjects with type 2 diabetes (T2D) on metformin. Diabetes. 2010;59:0077-OR
19. Kashiwagi A, Takinami Y, Kazuta K, Yoshida S, Utsuno A, Nagase I. Ipragliflozin improved glycaemic control with additional benefits of reductions of body weight and blood pressure in Japanese patients with type 2 diabetes mellitus: BRIGHTEN Study. Diabetologia. 2011;54:S68.
20. Grempler R, Thomas L, Eckhardt M, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterization and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab. 2012;14:83-90.
21. Seman L, Macha S, Nehmiz G, et al. Empagliflozin (BI 10773), a potent and selective SGLT-2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharm Drug Dev. 2013;2:152-61.
22. Komoroski B, Vachharajani N, Boulton D, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther. 2009;85:520-6.
23. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32:650-7.
24. Sha S, Devineni D, Ghosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose-dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab. 2011;13:669-72.
25. Schwartz SL, Akinlade B, Klasen S, Kowalski D, Zhang W, Wilpshaar W. Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus. Diabetes Technol Ther. 2011;13:1219-27.
26. Veltkamp SA, Kadokura T, Krauwinkel WJ, Smulders RA. Effect of Ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects. Clin Drug Investig. 2011;31:839-51.
27. List JF, Whaley JM. Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans. Kidney Int Suppl. 2011;120:S20-7.